Has John Burke, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,410,041 in general payments to John Burke, MD across 4,543 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Burke, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Burke, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Burke, MD

Hematology & Oncology · Aurora, CONPI 1801871215

Payments from drug & device makers

$25,410,041in general payments, 2019–2025

Across 4,543 payments — averaging $5593.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech, Inc.$9.2M
Beigene, Ltd.$6.2M
Astrazeneca UK Limited$2.5M
AstraZeneca$1.4M
Seagen Inc.$1.1M
AbbVie$869K
plus $4.1M from 39 others

$44,680in research payments, 2019–2025

Across 35 payments — averaging $1276.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$36K
Pfizer$6K
AbbVie$3K
TG Therapeutics, Inc.$16

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech, Inc.	1,711	$9,175,173
Beigene, Ltd.	120	$6,232,808
Astrazeneca UK Limited	21	$2,541,670
AstraZeneca	25	$1,444,614
Seagen Inc.	702	$1,079,751
AbbVie	62	$869,468
Merck	491	$844,099
Incyte Corporation	327	$416,480
Beone Medicines Ltd.	6	$387,760
Morphosys AG	356	$376,834
F. Hoffmann-la Roche AG	46	$370,004
Bristol Myers Squibb	23	$313,869
ADC Therapeutics America, Inc.	28	$259,466
Acerta Pharma LLC	8	$225,115
PTC Therapeutics, Inc.	20	$194,416
TG Therapeutics, Inc.	100	$145,914
E.r. Squibb & Sons, L.L.C.	18	$118,238
Pfizer	64	$93,818
Karyopharm Therapeutics Inc.	6	$90,825
Pharmacyclics LLC, An Abbvie Company	298	$65,581
Astellas Pharma Global Development	4	$45,367
Bayer	17	$20,143
Genmab U.S., Inc.	10	$14,512
Morphosys, US Inc.	10	$13,422
Adaptive Biotechnologies Corporation	6	$12,015
Genentech USA, Inc.	12	$10,486
Beigene USA, Inc.	7	$10,183
Ipsen Biopharmaceuticals, Inc	3	$6,680
Novartis	6	$6,345
Lilly USA, LLC	3	$4,494
Verastem, Inc.	2	$4,085
Gilead(2 entities)	8	$4,057
Beone Medicines USA, Inc.	2	$4,050
Eli Lilly	4	$3,600
Sanofi	2	$1,936
Novartis Pharma AG	2	$1,436
Epizyme, Inc.	1	$725
Medtronic	2	$304
Tempus AI, Inc	1	$94
Amgen	3	$57
Johnson & Johnson	2	$43
Takeda Pharmaceuticals U.S.A., Inc.	1	$29
CTI Biopharma Corp.	1	$28
Astellas Pharma US Inc	1	$26
Regeneron Healthcare Solutions, Inc.	1	$21

How this compares

$25,410,041 in reported general payments places this provider in the 95th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado →

Medicare billing

Part B allowed, 2024

$5,647,637

Medicare patients

946

Services billed

269,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Aurora

Elena ShagisultanovaAurora$22.4M
Elaine LamAurora$12.6M
Daniel PollyeaAurora$9.4M
Manali KamdarAurora$8.9M
Jennifer DiamondAurora$7.1M
Thomas FlaigAurora$5.9M
Ryan WeightAurora$2.9M
Sujatha NallapareddyAurora$1.7M
Sami DiabAurora$1.6M
Breelyn WilkyAurora$1.5M

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →